European equities traded in the US as American depositary receipts were tracking sharply lower late Tuesday morning, declining 1.71% to 1,313.74 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which rose 4.4% and 1.1% respectively. They were followed by accommodations booking platform trivago (TRVG), which rose 0.6%.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which fell 1.7% and 3.7% respectively. They were followed by oil and gas company TotalEnergies (TTE) and pharmaceutical company Novo Nordisk (NVO), which dropped 3.2% and 2.6% respectively.
From the UK and Ireland, the gainers were led by software firm Endava (DAVA) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which advanced 7.4% and 2.5% respectively. They were followed by biopharmaceutical companies NuCana (NCNA) and TC Biopharm (TCBP), which increased 2% and 1.9% respectively.
The decliners from the UK and Ireland were led by telecommunications operator Vodafone Group (VOD) and biopharmaceutical company Mereo BioPharma Group (MREO), which lost 7.9% and 5.1% respectively. They were followed by insurance firm Prudential (PUK) and pharmaceutical Silence Therapeutics (SLN), which dropped 5% and 4% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。